期刊文献+

西格列汀联合地特胰岛素治疗老年2型糖尿病的疗效及安全性观察 被引量:34

Therapeutic efficacy and safety of sitagliptin combined with insulin detemir against type 2 diabetes in elderly patients
原文传递
导出
摘要 目的:评价西格列汀联合地特胰岛素治疗老年2型糖尿病的疗效及安全性。方法:将88例口服降糖药控制不佳的老年2型糖尿病患者随机分成2组,观察组(西格列汀联合地特胰岛素组)和对照组(瑞格列奈联合地特胰岛素组)各44例;观察12周,比较治疗前后2组患者的空腹血糖(FPG)、餐后2 h血糖(2h PG)、糖化血红蛋白(Hb A1c)、空腹C肽(FC-P)、体重指数(BMI)、胰岛素用量及低血糖发生情况。结果:治疗后2组FPG、2h PG、Hb A1c均较治疗前显著降低(P<0.05),观察组FC-P较治疗前显著增高(P<0.05),BMI较治疗前略有下降,但无显著性差异(P>0.05),对照组FC-P及BMI较治疗前均无显著性差异(P>0.05);组间比较两组治疗后FPG、2h PG、Hb A1c无显著性差异(P>0.05),观察组FC-P较对照组显著增高(P<0.05),胰岛素用量显著减少(P<0.05),BMI显著下降(P<0.05)。观察组低血糖发生率较对照组显著降低(P<0.05)。结论:西格列汀联合地特胰岛素治疗老年2型糖尿病疗效确切,且可改善胰岛β细胞功能,安全性好。 OBJECTIVE To the therapeutic efficacy and safety of sitagliptin combined with insulin detemir against type 2 dia- betes in elderly patients. METHODS A total of 88 poorly controlled elderly patients with type 2 diabetes (T2DM) with oral antidiabetic drugs (OAD) were randomly divided into two groups to receive sitagliptin combined with insulin detemir (observa- tion group) or repaglinide combined with insulin detemir (control group) for 12weeks. The fasting blood glucose (FPG), 2 hour postprandial (2hPG), glyeated hemoglobin (HbAlc), fasting C-peptide (FC-P), body mass index (BMI), insulin dosage and incidence of hypoglycemia were compared between groups before versus after treatment. RESULTS FPG, 2hPG, HbAle were significantly decreased among two groups after treatment (P〈0. 05). FC-P was significantly increased in observation group after treatment (P〈0. 05), while BMI was slightly decreased(P〉0. 05). FC-P and BMI in control groups had no signif- icant changes (P〉0. 05). No significant difference was observed in FPG, 2hPG, HbAlc between groups after treatment (P〉0. 05). FC-P was significantly higher in observation group than in control group (P〈0. 05), insulin dosage and BMI were de- creased significantly (P〈0. 05). The incidence of hypoglycemia was significantly lower in observation group than in control group (P〈0. 05). CONCLUSION Sitagliptin combined detemir has therapeutic effieaey and good security in elderly patients with type 2 diabetics, and can improve islet β-cell functions.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2015年第10期949-951,共3页 Chinese Journal of Hospital Pharmacy
关键词 西格列汀 地特胰岛素 糖尿病 疗效 安全性 sitagliptin insulin detemir diabetes efficacy safety
  • 相关文献

参考文献10

二级参考文献39

  • 1张家庆.HOMA2-IR是个较好的胰岛素抵抗指数[J].中华内分泌代谢杂志,2005,21(4):304-305. 被引量:60
  • 2杨文英.如何选择不同的胰岛素治疗方案以提高胰岛素治疗的技巧[J].国际内分泌代谢杂志,2006,26(3):195-197. 被引量:62
  • 3Ole Schmitz.长效胰岛素类似物的应用现状[J].国际内分泌代谢杂志,2006,26(3):197-198. 被引量:12
  • 4潘长玉,主译.Joslin糖尿病学[M].14版.北京:人民卫生出版社,2007:1193.
  • 5Buse JB,Polon sky KS,Burant CF. Type 2 diabetes Mellitus. In:Kronenberg HM, Melmed S, Polonsky KS, etal. Williams Textbook of Endocrinology[M], llth ed. Philadeb phia,PA : Saunders,2008 : 1329-1389.
  • 6Del Prato S, Marchetti P. Betaand alphacell dysfunction in type 2 diabetes[J]. Horm Metab Res,2004,36,775-781.
  • 7Muller WA, Faloona GR, AguilarParada E, et al. Abnormal alpha-cell function in diabetes : response to carbohydrate and protein Ingestion[J]. N Engl J Meal,1970,283:109-115.
  • 8Mohan V,Yang W,Son HY,et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and korea[J]. Diabetes Res Clin Pract, 2009,83 (1):106-116.
  • 9Doyle ME, Egan JM. Mechanisms of glucagon-like peptidel in the pancreas [ J ]. Pharmacol Ther,2007,113 ( 3 ) :546-593.
  • 10Kim W, Egan JM. The role of inm'etins in glucose homeostasis and diabetes treatment [J]. Pharmacol Rev,2008,60 (4) :470-512.

共引文献57

同被引文献218

  • 1杜玉茗,宋利华,尚涛,杜建鹏.老年2型糖尿病患者胰岛素加用二肽基肽酶Ⅳ抑制剂治疗的安全性及疗效[J].中国老年学杂志,2014,34(10):2688-2689. 被引量:6
  • 2吕霄,赵猛,凌宏威,李伟.西格列汀对糖尿病前期人群的干预效果[J].中国老年学杂志,2014,34(1):26-29. 被引量:27
  • 3Kretltz A J, Patel MB, Bailey CL New drugs for type 2 diabetes mellitus: what is their place in therapy?[J]. Drugs, 2008, 68(15): 2131-2162.
  • 4Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors[J]. Drugs, 2011, 71(11): 1441-1467.
  • 5Buteau J, EI-Assaad W, Rhodes CJ, et al. Glucagon-like pepfide-1 prevents beta cell glucolipotoxicity[J]. Diabetologia, 2004, 47(5): 806-815.
  • 6Schreiber SA, Haak T. Insuling glargine benefits patients with type 2 diabetes inadeguately controlled on oral antidabetic treatment: an observati-onal study of everyday practice in 12,216 patients[J]. Diabetes Obes Metab, 2007, 9(1): 31-38.
  • 7Phung OJ, Scholle JM, Taluar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes[J]. JAMA, 2010, 303(14): 1410-1418.
  • 8Monami M, Iacomelli I, Marehionni N, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials[J]. Nutr Metab Cardiovasc Dis, 2010, 20(2): 224-235.
  • 9Monami M, Cremasco F, Lamanna C, et al. Predictors of response to dipeptidyl pcptidase-4 inhibitors: evidence from randomized clinical trials[J]. Diabetes Metab Res Rev, 2011, 27(2): 362-372.
  • 10Scheen AJ, Charpentier G, Ostgren C J, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus[J]. Diabetes Metab Res Rev, 2010, 26(3): 540-549.

引证文献34

二级引证文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部